Mangoceuticals, Inc. (MGRX) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.05
↓-98% vs avg
5yr avg: 3.05
30Y Low0.3·High5.8
ROE
↑
-118.3%
↓+83% vs avg
5yr avg: -704.7%
30Y Low-118%·High-118%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MGRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mangoceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $6M | $5M | $4M | — | — |
| Enterprise Value | $6M | $5M | $4M | — | — |
| P/E Ratio → | -0.08 | — | — | — | — |
| P/S Ratio | 9.28 | 7.78 | 6.09 | — | — |
| P/B Ratio | 0.05 | 0.34 | 5.75 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MGRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 8.03 | 5.26 | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
MGRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Mangoceuticals, Inc. earns an operating margin of -1294.4%. Operating margins have expanded from -22279.7% to -1294.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -118.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 61.7% | 61.7% | 59.0% | 54.3% | — |
| Operating Margin | -1294.4% | -1294.4% | -1260.3% | -22279.7% | — |
| Net Profit Margin | -1413.6% | -1413.6% | -1259.4% | -22352.1% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -118.3% | -118.3% | -1326.7% | -669.0% | — |
| ROA | -106.0% | -106.0% | -897.0% | -389.5% | -78.5% |
| ROIC | -83.8% | -83.8% | -3083.5% | -1051.8% | — |
| ROCE | -107.8% | -107.8% | -1165.2% | -548.7% | — |
MGRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $156309 ($214962 total debt minus $58653 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.17 | 0.57 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | 0.01 | -0.79 | -0.54 | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -581.90 | -581.90 | — | -307.68 | -96.80 |
MGRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.05x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.67x to 0.05x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 0.05 | 0.05 | 3.88 | 2.67 | 0.57 |
| Quick Ratio | 0.05 | 0.05 | 3.79 | 2.67 | 0.57 |
| Cash Ratio | 0.04 | 0.04 | 3.50 | 2.62 | 0.57 |
| Asset Turnover | — | 0.04 | 0.70 | 0.01 | — |
| Inventory Turnover | — | — | 16.21 | — | — |
| Days Sales Outstanding | — | — | — | — | — |
MGRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mangoceuticals, Inc. returns 100.0% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 16.7% | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 100.0% | 16.7% | 0.0% | — | — |
| Shares Outstanding | — | $2M | $1M | $1M | $997666 |
Peer Comparison
Compare MGRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MGRXYou | $6M | -0.1 | — | — | 61.7% | -1294.4% | -118.3% | -83.8% | — |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 AMWL | $119M | -1.2 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 TDOC | $1B | -6.0 | 14.8 | 4.3 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 OPRX | $121M | 24.0 | 6.4 | 6.5 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 WELL | $152B | 155.7 | 67.4 | 53.3 | 39.2% | 3.3% | 2.5% | 0.5% | 8.6 |
 DOCS | $5B | 23.1 | 20.8 | 19.4 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 NUVB | $2B | -8.4 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 ATAI | $1B | -4.5 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See MGRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MGRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MGRX vs HIMS
Side-by-side business, growth, and profitability comparison vs Hims & Hers Health, Inc..
Start ComparisonMGRX — Frequently Asked Questions
Quick answers to the most common questions about buying MGRX stock.
What is Mangoceuticals, Inc.'s P/E ratio?
Mangoceuticals, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Mangoceuticals, Inc.'s ROE?
Mangoceuticals, Inc.'s return on equity (ROE) is -118.3%. The historical average is -118.3%.
Is MGRX stock overvalued?
Based on historical data, Mangoceuticals, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Mangoceuticals, Inc.'s dividend yield?
Mangoceuticals, Inc.'s current dividend yield is 100.00%.
What are Mangoceuticals, Inc.'s profit margins?
Mangoceuticals, Inc. has 61.7% gross margin and -1294.4% operating margin.